{平台标识} {固定描述} Canaccord Genuity has raised its price target on Biodesix (BDSX), citing increased revenue assumptions. The analyst revision reflects growing confidence in the company’s diagnostic product portfolio and market position. Biodesix specializes in lung cancer testing and precision medicine.
Canaccord Genuity Raises Biodesix Price Target on Upgraded Revenue Forecast - {财报副标题}
News Analysis
© 2026 Market Analysis. All data is for informational purposes only.